Bristol Myers Squibb management check
BMY · Health Care · Pharmaceuticals · CEO Dr. Chris Boerner
Filings as of
4 good · 1 to watch · 1 flagged, across the seven questions below.
- Flag
Have owners done well?
Trailed its chosen peers$100 invested at the start of fiscal 2021 grew to $105, against $198 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.98 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good
What does the CEO cost owners?
0.3% of net income$21.9m of reported pay in fiscal 2025, against $7.1bn of net income.
- n/a
Do they own the stock?
No recent CEO filingLight activity: no buys, $437k sold in six months.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -0.9% a year over the last three fiscal years. Stock-based pay was 1.1% of revenue in the latest year.
- Watch
Is leadership stable?
2 CEOs in the pay tableCEOs in the pay table: Dr. Giovanni Caforio, Dr. Chris Boerner. 6 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 0 | 26 | |
| Pay for performance | 99 | 85 | |
| CEO cost | 92 | 44 | |
| Skin in the game | — | — | 46 |
| Dilution | 62 | 68 | |
| Stable leadership | 55 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Pharmaceuticals, by management score. Bristol Myers Squibb is 24th of 60 in its sector.
- 32LLYLilly (Eli)84
- 181ZTSZoetis70
- 190JNJJohnson & Johnson69
- 207BMYBristol Myers Squibb68
- 263PFEPfizer64
- 323MRKMerck & Co.60
- 369VTRSViatris57
Pay versus performance
From the proxy statement filed March 25, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Dr. Chris Boerner | $21.9m | $16.9m | $9.2m | $105 | $198 | $7.1bn |
| 2024 | Dr. Chris Boerner | $18.8m | $21.2m | $7.7m | $105 | $154 | −$8.9bn |
| 2023 | Dr. Giovanni Caforio | $19.7m | $383k | $5.9m | $91 | $142 | $8.0bn |
| 2022 | Dr. Giovanni Caforio | $20.1m | $35.1m | $7.0m | $123 | $139 | $6.3bn |
| 2021 | Dr. Giovanni Caforio | $19.8m | $16.5m | $7.1m | $103 | $126 | $7.0bn |
The board says pay is tied most to total revenues. Its other key measures: Revenue, SSI Scorecard, Pipeline, Stock Price, Operating Income, Relative TSR.
Insiders and the CEO's stake
Light activity: no buys, $437k sold in six months.
- SoldCristian MassacesiEVP,Chief Med Offr,Head of Dev$403kSep 9, 2026
- SoldPhil M HolzerSVP and Controller$34kAug 25, 2026
Leadership and governance on file
- Jul 25, 2025Leadership change8-K 5.02
- Feb 18, 2025Leadership change8-K 5.02
- Jun 18, 2024Leadership change8-K 5.02
- Mar 18, 2024Leadership change8-K 5.02
- Feb 15, 2024Leadership change8-K 5.02
- Oct 31, 2023Leadership change8-K/A 5.02
- May 4, 2023Leadership change8-K 5.02
- Apr 26, 2023Leadership change8-K 5.02
- Jan 31, 2023Leadership change8-K 5.02
- Jun 15, 2022Leadership change8-K 5.02
- Mar 17, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 8, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $43.1bn returned to owners in buybacks and dividends, 222% of net income, and $2.6bn of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $46.4bn | $46.2bn | $45.0bn | $48.3bn | $48.2bn |
| Net income | $7.0bn | $6.3bn | $8.0bn | −$8.9bn | $7.1bn |
| Stock-based pay | $583.0m | $457.0m | $518.0m | $507.0m | $553.0m |
| Buybacks | $6.3bn | $8.0bn | $5.2bn | $0 | $0 |
| Dividends | $4.4bn | $4.6bn | $4.7bn | $4.9bn | $5.0bn |
| Diluted shares | 2245m | 2146m | 2078m | 2027m | 2039m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.